Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
D000544:Alzheimer Disease / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive / Q000379:methods* / Q000639:trends; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends; D008590:Meningoencephalitis / Q000139:chemically induced; D051379:Mice; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000276:immunology; D016896:Treatment Outcome; D014612:Vaccines / Q000009:adverse effects / Q000627:therapeutic use
C437846:AN-1792; D016229:Amyloid beta-Peptides; D000906:Antibodies; D000911:Antibodies, Monoclonal; D010446:Peptide Fragments; D014612:Vaccines